Cloning of sequences induced and suppressed by administration of PSK, antitumor protein-bound polysaccharide. 1985

K Hirose, and M Hakozaki, and K Matsunaga, and C Yoshikumi, and T Hotta, and M Yanagisawa, and M Yamamoto, and H Endo

To elucidate the effects of PSK, a protein-bound polysaccharide from Coriolus versicolor, on gene expression in tumor cells, we prepared cDNA clone libraries from PSK-treated and untreated cells of a rat ascites hepatoma line, AH66, which was previously shown to be susceptible to the antitumor action of this compound. Two PSK-induced and one suppressed cDNA clones were selected from these libraries by using a differential colony hybridization and RNA blot hybridization. PSK was thus shown to have a direct effect on the transcription and consequently on the translation of tumor cells.

UI MeSH Term Description Entries
D008114 Liver Neoplasms, Experimental Experimentally induced tumors of the LIVER. Hepatoma, Experimental,Hepatoma, Morris,Hepatoma, Novikoff,Experimental Hepatoma,Experimental Hepatomas,Experimental Liver Neoplasms,Hepatomas, Experimental,Neoplasms, Experimental Liver,Experimental Liver Neoplasm,Liver Neoplasm, Experimental,Morris Hepatoma,Novikoff Hepatoma
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009693 Nucleic Acid Hybridization Widely used technique which exploits the ability of complementary sequences in single-stranded DNAs or RNAs to pair with each other to form a double helix. Hybridization can take place between two complimentary DNA sequences, between a single-stranded DNA and a complementary RNA, or between two RNA sequences. The technique is used to detect and isolate specific sequences, measure homology, or define other characteristics of one or both strands. (Kendrew, Encyclopedia of Molecular Biology, 1994, p503) Genomic Hybridization,Acid Hybridization, Nucleic,Acid Hybridizations, Nucleic,Genomic Hybridizations,Hybridization, Genomic,Hybridization, Nucleic Acid,Hybridizations, Genomic,Hybridizations, Nucleic Acid,Nucleic Acid Hybridizations
D011509 Proteoglycans Glycoproteins which have a very high polysaccharide content. Proteoglycan,Proteoglycan Type H
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA

Related Publications

K Hirose, and M Hakozaki, and K Matsunaga, and C Yoshikumi, and T Hotta, and M Yanagisawa, and M Yamamoto, and H Endo
January 1988, International journal of immunopharmacology,
K Hirose, and M Hakozaki, and K Matsunaga, and C Yoshikumi, and T Hotta, and M Yanagisawa, and M Yamamoto, and H Endo
January 1994, In vivo (Athens, Greece),
K Hirose, and M Hakozaki, and K Matsunaga, and C Yoshikumi, and T Hotta, and M Yanagisawa, and M Yamamoto, and H Endo
January 1988, International journal of immunopharmacology,
K Hirose, and M Hakozaki, and K Matsunaga, and C Yoshikumi, and T Hotta, and M Yanagisawa, and M Yamamoto, and H Endo
January 1991, Anticancer research,
K Hirose, and M Hakozaki, and K Matsunaga, and C Yoshikumi, and T Hotta, and M Yanagisawa, and M Yamamoto, and H Endo
September 1984, Journal of pharmacobio-dynamics,
K Hirose, and M Hakozaki, and K Matsunaga, and C Yoshikumi, and T Hotta, and M Yanagisawa, and M Yamamoto, and H Endo
January 1992, Biotherapy (Dordrecht, Netherlands),
K Hirose, and M Hakozaki, and K Matsunaga, and C Yoshikumi, and T Hotta, and M Yanagisawa, and M Yamamoto, and H Endo
June 1993, Biological & pharmaceutical bulletin,
K Hirose, and M Hakozaki, and K Matsunaga, and C Yoshikumi, and T Hotta, and M Yanagisawa, and M Yamamoto, and H Endo
May 1989, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
K Hirose, and M Hakozaki, and K Matsunaga, and C Yoshikumi, and T Hotta, and M Yanagisawa, and M Yamamoto, and H Endo
September 1987, Journal of clinical & laboratory immunology,
K Hirose, and M Hakozaki, and K Matsunaga, and C Yoshikumi, and T Hotta, and M Yanagisawa, and M Yamamoto, and H Endo
March 2009, Anticancer research,
Copied contents to your clipboard!